Joel Greenblatt: The Magic Formula That Beat the Market

From 1985 to 2005, Joel Greenblatt's Gotham Capital compounded at roughly 40% a year — a run so improbable that rival fund managers begged to know the secret. His answer was almost insulting in its simplicity: buy good companies when they're cheap.

The Origin Story

Joel Greenblatt didn't start with a screen. He started in the overlooked alleys of the market — spinoffs, merger securities, bankruptcies, and recapitalizations — the messy situations most analysts couldn't be bothered to model.

He launched Gotham Capital in 1985 with around $7 million, much of it backed by junk-bond financier Michael Milken's circle. Over the next two decades, the fund's returns became the stuff of legend, reportedly compounding near 40% a year before he returned outside capital in 1995 to keep managing the partnership's own money.

Greenblatt's edge was never speed or information — it was a willingness to do the unglamorous work in places where competition was thin. He later distilled that approach into two best-selling books and a teaching career at Columbia Business School, turning a niche style into a public playbook.

What Is Greenblatt's Magic Formula?

It's a two-factor screen: rank every large company by earnings yield and by return on capital, then buy the basket that scores best on both combined. That's the entire engine.

Earnings yield (roughly operating earnings divided by enterprise value) measures how cheap a business is. Return on capital (operating earnings divided by the capital the business actually uses) measures how good it is. Greenblatt's insight was that combining cheap and good, mechanically, beats chasing either one alone.

He published the method in 2005's The Little Book That Beats the Market, and backtests suggested the ranked basket handily outperformed the index over long horizons. The discipline overlaps heavily with our fundamental analysis framework — it is essentially a quality-and-value filter run without emotion.

Greenblatt's Philosophy in His Own Words

Greenblatt's writing is famous for making hard ideas sound obvious. "The secret to investing is to figure out the value of something — and then pay a lot less," he wrote, compressing Benjamin Graham's entire margin-of-safety doctrine into a single sentence.

He was equally blunt about temperament. "Choosing individual stocks without any idea of what you're looking for is like running through a dynamite factory with a burning match," he warned — a reminder that a process beats a hunch.

His deepest point is that the Magic Formula works precisely because it sometimes doesn't — its stretches of underperformance are the price that scares away enough competitors to keep the edge alive. That paradox sits at the heart of why most investors can't replicate it. For more on this mindset, see our super investors profiles.

5 Key Principles

First, buy good and cheap together. A wonderful business at a fair price and a fair business at a wonderful price both fail the test — Greenblatt wants both boxes ticked at once.

Second, value the business, then demand a discount. Price is what you pay; value is what you estimate. The gap between them is your margin of safety.

Third, embrace the boring. Spinoffs, restructurings, and forgotten corners of the market are where mispricing hides, because the crowd isn't looking.

Fourth, let the process override emotion. A mechanical ranking removes the temptation to fall in love with a story or panic in a drawdown.

Fifth, be patient to the point of stubbornness. The formula's long flat patches are a feature, not a bug — they are what create the opportunity in the first place.

Does the Magic Formula Still Work?

Yes — but only for the patient. The math that made it work in 1985 hasn't changed: cheap, high-return businesses still tend to outperform expensive, low-return ones over long stretches.

The honest caveat is that it can lag the market for years at a time. Critics argue that as screening became universal and capital crowded into "quality value," some of the edge compressed — and a strategy that trails for three or four years will shake out almost everyone who tries it.

That fragility is also its durability. A strategy easy to copy but psychologically brutal to hold is one of the few edges that survives being published in a best-seller. The formula didn't stop working; most people simply can't sit through the stretches when it doesn't. Understanding that loop is half of trading basics.

The Stocks the Magic Formula Surfaces

The formula doesn't care about narratives — it cares about the math of quality and value. The names it tends to surface are durable, cash-generative businesses trading at reasonable multiples, not speculative moonshots.

Here is the type of company that scores well on the combined earnings-yield and return-on-capital ranking:

These are illustrative, not recommendations — the point is the profile. Businesses like Microsoft (MSFT), Alphabet (GOOGL), and UnitedHealth (UNH) screen well because they pair genuine returns on capital with valuations that aren't absurd, while defensives such as Johnson & Johnson (JNJ) and value-tilted names like AbbVie (ABBV) round out the quality-and-cheap mix alongside Home Depot (HD) and Meta Platforms (META).

What Can Everyday Investors Learn From Greenblatt?

The biggest lesson is that a simple, repeatable process beats a brilliant, improvised one. You don't need Greenblatt's spinoff expertise to apply his core idea — buy quality businesses at a discount and refuse to overpay.

The second lesson is psychological. Greenblatt's entire edge survives because most people lack the patience to endure the lean years. Whatever method you choose, the discipline to stick with it through underperformance is rarer — and more valuable — than the method itself.

The third is humility about timing. Greenblatt never claimed to know when his stocks would work; he only insisted that, bought cheap enough, they eventually would. That separation of "what to own" from "when it pays off" is the quiet genius behind one of investing's best long-run records of patient compounding.

Ready to analyze these stocks yourself? Search any ticker on MainRatios to see valuations from 6 legendary investors - free.